MicroPort CardioFlow Medtech 미래 성장
Future 기준 확인 5/6
MicroPort CardioFlow Medtech is forecast to grow earnings and revenue by 102.9% and 23.5% per annum respectively. EPS is expected to grow by 103% per annum. Return on equity is forecast to be 1.4% in 3 years.
주요 정보
102.9%
수익 성장률
103.0%
EPS 성장률
Medical Equipment 수익 성장 | 39.2% |
매출 성장률 | 23.5% |
향후 자기자본 수익률 | 1.4% |
애널리스트 커버리지 | Low |
마지막 업데이트 | 01 Oct 2024 |
최근 미래 성장 업데이트
Recent updates
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable
Sep 27After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar
Sep 27Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?
Aug 07Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding
Jun 19MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
May 29MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Apr 05We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Feb 23An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued
Jan 18Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth
Oct 04Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%
May 31We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
May 23The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts
Apr 06MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans
Feb 08We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth
Oct 18We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Jun 30Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts
Apr 04MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 03An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued
Jan 21Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?
Sep 05We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn
Jun 07Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)
May 03수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 753 | 99 | 8 | 23 | 3 |
12/31/2025 | 571 | -39 | -99 | -94 | 3 |
12/31/2024 | 454 | -162 | -70 | -45 | 2 |
6/30/2024 | 383 | -349 | -182 | -167 | N/A |
3/31/2024 | 360 | -410 | -210 | -187 | N/A |
12/31/2023 | 336 | -472 | -237 | -207 | N/A |
9/30/2023 | 319 | -491 | -250 | -216 | N/A |
6/30/2023 | 303 | -511 | -263 | -226 | N/A |
3/31/2023 | 277 | -483 | -247 | -204 | N/A |
12/31/2022 | 251 | -454 | -232 | -183 | N/A |
9/30/2022 | 245 | -345 | -270 | -191 | N/A |
6/30/2022 | 239 | -236 | -309 | -199 | N/A |
3/31/2022 | 220 | -209 | -290 | -180 | N/A |
12/31/2021 | 201 | -183 | -270 | -162 | N/A |
9/30/2021 | 176 | -265 | N/A | N/A | N/A |
6/30/2021 | 151 | -346 | N/A | N/A | N/A |
3/31/2021 | 128 | -372 | N/A | N/A | N/A |
12/31/2020 | 104 | -398 | -168 | -110 | N/A |
12/31/2019 | 22 | -145 | -191 | -143 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 2160 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
수익 vs 시장: 2160 is forecast to become profitable over the next 3 years, which is considered above average market growth.
고성장 수익: 2160 is expected to become profitable in the next 3 years.
수익 대 시장: 2160's revenue (23.5% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
고성장 수익: 2160's revenue (23.5% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 2160's Return on Equity is forecast to be low in 3 years time (1.4%).